Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: Results from a prospective community oncology study

Journal of Clinical Oncology

Volumn 16, Issue 10, 1998, Pages 3412-3425

  Demetri, George D ^a   Kris, Mark ^a   Wade, James ^a   Degos, Laurent ^a   Cella, David ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; FOLINIC ACID; NAVELBINE; PACLITAXEL; RECOMBINANT ERYTHROPOIETIN; VINCRISTINE;

ADULT; AGED; ANEMIA; ARTICLE; BLOOD TRANSFUSION; CANCER; CANCER CHEMOTHERAPY; CHEMOSENSITIVITY; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; FEVER; GRANULOCYTOPENIA; HEMOGLOBIN DETERMINATION; HORMONE BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; QUALITY OF LIFE; RETICULOCYTE COUNT; SEX DIFFERENCE; SUBCUTANEOUS DRUG ADMINISTRATION; WELLBEING;

EID: 0031785826     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1998.16.10.3412     Document Type: Article

References (25)

1. Cella D: The Functional Assessment of Cancer Therapy-Anemia (FACT-An) scale: A new tool for the assessment of outcomes in cancer anemia and fatigue. Semin Hematol 34:13-19, 1997 (suppl 2)
2. Leitgeb C, Pecherstorfer M, Fritz E, et al: Quality of life in chronic anemia of cancer during treatment with recombinant human erythropoietin. Cancer 73:2535-2542, 1994
3. Ludwig H, Sundal E, Pecherstorfer M, et al: Recombinant human erythropoietin for the correction of cancer-associated anemia with and without concomitant cytotoxic chemotherapy. Cancer 76:2319-2329. 1995
4. Skillings JR, Sridhar FG, Wong C, et al: The frequency of red cell transfusion for anemia in patients receiving chemotherapy. Am J Clin Oncol 16:22-25, 1993
5. Miller CB, Jones RJ, Piantadosi S, et al: Decreased erythropoietin response in patients with the anemia of cancer. N Engl J Med 322:1689-1692, 1990
6. Spivak JL: Cancer-related anemia: Its causes and characteristics. Semin Oncol 21:3-8, 1994 (suppl 3)
7. Abels R: Erythropoietin for anaemia in cancer patients. Eur J Cancer 29A: S2-S8, 1993 (suppl 2)
8. Dunphy FR, Dunleavy TL, Harrison BR, et al: Erythropoietin reduces anemia and transfusions after chemotherapy with paclitaxel and carboplatin. Cancer 79:1623-1628, 1997
9. Platanias LC, Miller CB, Mick R, et al: Treatment of chemotherapy-induced anemia with recombinant human erythropoietin in cancer patients. J Clin Oncol 9:2021-2026, 1991
10. Glaspy J, Bukowski R, Steinberg D, et al: Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. J Clin Oncol 15:1218-1234, 1997
11. Yellen SB, Cella DF, Webster K, et al: Measuring fatigue and other anemia-related symptoms with the Functional Assessment of Cancer Therapy (FACT) measurement system. J Pain Symptom Manage 13:63-74, 1997
12. Diggle P, Liang K-Y, Zeger SL: Analysis of Longitudinal Data. Oxford, Clarendon Press, 1993
13. Little RJA, Rubin DB: Statistical Analysis With Missing Data. New York, NY, Wiley, 1987
14. Cella DF, Bonomi AE: Measuring quality of life: 1995 Update. Oncology 9:47-60, 1995 (suppl 11)
15. Coates A, Gebski V, Bishop JF, et al: Improving the quality of life during chemotherapy for advanced breast cancer: A comparison of intermittent and continuous treatment strategies. N Engl J Med 317:1490-1495, 1987
16. Tannock IF, Boyd NF, DeBoer G, et al: A randomized trial of two dose levels of cyclophosphamide, methotrexate, and fluorouracil chemotherapy for patients with metastatic breast cancer. J Clin Oncol 6:1377-1387, 1988
17. Gough IR, Furnival CM, Schilder L, et al: Assessment of the quality of life of patients with advanced cancer. Eur J Cancer Clin Oncol 19:1161-1165, 1983
18. McCormack HM, de L Horne DJ, Sheather S: Clinical applications of visual analog scales: A critical review. Psychol Med 18:1007-1019, 1988
19. Pedrazzoli P, Ponchio L, Poggi G, et al: Response to recombinant human erythropoietin (rHuEpo) in patients with cancer-related anaemia. Eur J Cancer 29:S53, 1993 (suppl 6, abstr 260)
20. Rose E, Rai K, Revicki D, et al: Clinical and health status assessments in anemic chronic lymphocytic leukemia (CLL) patients treated with epoetin alfa (EPO). Blood 84:526a, 1994 (suppl 1, abstr 2091)
21. Cella DF, Tulsky DS, Gray G, et al: The Functional Assessment of Cancer Therapy (FACT) scale: Development and validation of the general measure. J Clin Oncol 11:570-579, 1993
22. Brady MJ, Cella DF, Mo F, et al: Reliability and validity of the Functional Assessment of Cancer Therapy-Breast (FACT-B) quality-of-life instrument. J Clin Oncol 15:974-986, 1997
23. Cella DF, Bonomi AE, Lloyd SR, et al: Reliability and validity of the Functional Assessment of Cancer Therapy-Lung (FACT-L) quality-of-life instrument. Lung Cancer 12:199-220, 1995
24. Henry D, Abels R, Larholt K: Prediction of response to recombinant human erythropoietin (rHuEPO/epoetin-a) therapy in cancer patients. Blood 85:1676-1678, 1995
25. Ludwig H, Fritz E, Leitgeb C, et al: Prediction of response to erythropoietin treatment in chronic anemia of cancer. Blood 84:1056-1063, 1994